Human safety and genetically modified plants: a review of antibiotic resistance markers and future transformation selection technologies.
Goldstein
D A
DA
The Monsanto Company, St Louis, MO 63017, USA. daniel.a.goldstein@monsanto.com
Tinland
B
B
Gilbertson
L A
LA
Staub
J M
JM
Bannon
G A
GA
Goodman
R E
RE
McCoy
R L
RL
Silvanovich
A
A
D000668:Ampicillin Resistance / Q000235:genetics; D000890:Anti-Infective Agents; D015415:Biomarkers; D002934:Cinnamates / Q000378:metabolism; D018744:DNA, Plant / Q000235:genetics; D004351:Drug Resistance / Q000235:genetics*; D006801:Humans; D006921:Hygromycin B / Q000031:analogs & derivatives / Q000378:metabolism; D007613:Kanamycin Resistance / Q000235:genetics; D009355:Neomycin / Q000378:metabolism; D010940:Plant Proteins / Q000235:genetics; D030821:Plants, Genetically Modified / Q000009:adverse effects / Q000235:genetics*; D045522:Recombinases / Q000378:metabolism; D000198:Spectinomycin; D013307:Streptomycin / Q000378:metabolism; D014169:Transformation, Bacterial / Q000235:genetics; D001618:beta-Lactamases / Q000235:genetics
D000890:Anti-Infective Agents; D015415:Biomarkers; D002934:Cinnamates; D018744:DNA, Plant; D010940:Plant Proteins; D045522:Recombinases; D006921:Hygromycin B; C026273:hygromycin A; D000198:Spectinomycin; D001618:beta-Lactamases; C034413:beta-lactamase TEM-1; D009355:Neomycin; D013307:Streptomycin